Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
- Dec 5, 2016Presentations Include Analysis of Real-World Use and Post-Hoc Analysis of Long-Term Safety and Efficacy
Eisai Inc. announced today new analyses and data on perampanel presented at the 2016 Annual Meeting of the American Epilepsy Society (AES). Perampanel, marketed as FYCOMPA® CIII, is indicated as...
- Dec 5, 2016
Eisai Inc. announced today final results of its Phase 3 open-label two-year study of rufinamide, which were presented at the 2016 Annual Meeting of the American Epilepsy Society (AES) held from...
- Dec 1, 2016
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced the immediate appointment of Rebecca Jolley as Senior Vice President Americas Commercial, Oncology Business...
-
Nov 30, 2016
Eisai Inc. announced today the presentation of new data from studies of eribulin, marketed under the brand name Halaven®, at the 2016 San Antonio Breast Cancer Symposium (SABCS). Two ongoing...
- Nov 28, 2016
Eisai Inc. announced today the presentation of 12 posters during the 70th annual American Epilepsy Society (AES) Annual Meeting, highlighting data from the company's anti-epileptic drugs FYCOMPA®...
